Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

Background There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for p...

Full description

Saved in:
Bibliographic Details
Main Authors: Dmitriy Zamarin, Siqing Fu, Elad Sharon, Travis J Hollmann, Alexia Iasonos, Jason A Konner, Susan C Modesitt, Qin Zhou, Alexandre Buckley De Meritens, Carol Aghajanian, Claire F Friedman, Panagiotis A Konstantinopoulos, Bradley R Corr, Michael A Carducci, Alexandra Snyder Charen
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001126.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001126.full

Similar Items